Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lipocalin-2 (LCN2) is a potent bacteriostatic protein. We aimed to investigate its role as a disease activity marker in patients with inflammatory bowel disease (IBD) and its induction by the Th17 cytokines IL-17A, IL-22, and TNF-α in colonic epithelial cells. Moreover, we analyzed the influence of IBD-associated IL23R alleles on LCN2 serum levels in IBD patients. METHODS: LCN2 serum levels were determined in 131 IBD patients (71 with Crohn's disease [CD], 60 with ulcerative colitis [UC]) and 63 healthy controls. IBD patients were genotyped for 10 IBD-associated IL23R polymorphisms. LCN2 expression after stimulation with IL-17A, IL-22, and TNF-α was measured in human colonic epithelial cell lines. RESULTS: A significant upregulation of serum LCN2 in active IBD (median [IQR], 36.84 [21.17-73.74] ng/mL; P = 0.01) compared with healthy controls (24.22 [17.76-35.25] ng/mL) was confined to active UC (42.21 [28.97-73.74] ng/mL; P = 0.0006). LCN2 proved to be a marker of UC disease activity (area under the curve 0.75, sensitivity 0.83, specificity 0.63; P = 0.0002). IL-17A showed a synergistic effect with IL-22 and TNF-α in inducing colonic epithelial expression of LCN2 and its essential transcription factor IKBZ. In CD, LCN2 concentrations were significantly modulated by IL23R genotype status with homozygous carriers of IBD risk-increasing alleles showing particularly low LCN2 levels. CONCLUSIONS: Serum LCN2 proves to be a biomarker of active UC. Lower LCN2 levels in CD patients carrying IBD risk-increasing IL23R variants may result from a restricted upregulation of LCN2 due to an impaired Th17 immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Self-citationA Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 1×
“IL-17A itself, along with IL-22, is known to promote the expression of antimicrobial peptides, such as S100 proteins, in epithelial cells as integral part of the mucosal host defense.(6,7) The heteromeric protein complex formed by S100A8 and S100A9, termed calprotectin, has evolved as a suitable biomarker for monitori…”
BackgroundLipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron
Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., & Aderem, A. (2004) · Nature · doi:10.1038/nature03104 · Cited by 1,877 · cited 1×
“As a component of the innate immune system, it serves as a siderophore binding protein that prevents bacteria from acquisition of siderophore bound iron and therefore limits bacterial growth.(10) High LCN2 expression by gut epithelial cells has been demonstrated in colonic biopsies from inflamed areas of patients with…”
BackgroundIncreased expression of interleukin 17 in inflammatory bowel disease
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., & Fujiyama, Y. (2003) · Gut · doi:10.1136/gut.52.1.65 · Cited by 1,713
Goetz, D. H., Holmes, M. A., Borregaard, N., Bluhm, M. E., Raymond, K. N., & Strong, R. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00708-6 · Cited by 1,355
Raffatellu, M., George, M. D., Akiyama, Y., Hornsby, M. J., Nuccio, S.-P., Paixao, T. A., Butler, B. P., Chu, H., Santos, R. L., Berger, T., et al. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.03.011 · Cited by 525 · cited 8×
“12 This effect is further amplified by addition of IL-17A, making LCN2 one of the main intestinal epithelial endpoints of the IL-23/Th17 effector pathway through IL-17A and IL-22.”
BackgroundInfluentialBerger, T., Togawa, A., Duncan, G. S., Elia, A. J., You-Ten, A., Wakeham, A., Fong, H. E. H., Cheung, C. C., & Mak, T. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510847103 · Cited by 460 · cited 1×
“A deficiency in LCN2 in turn is known to impair neutrophilic function and enhance susceptibility to bacterial infections.(38,39) In a detailed investigation of the short-term IBD mouse model anti-CD40 Rag22/2, LCN2 has been identified as one of the few candidate biomarkers downstream of IL-23 signaling whose upregulat…”
BackgroundKarlsen, J. R., Borregaard, N., & Cowland, J. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017129 · Cited by 146
Liu, Z., Petersen, R., & Devireddy, L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202411 · Cited by 64
Cited by
Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation
Moschen, A. R., Adolph, T. E., Gerner, R. R., Wieser, V., & Tilg, H. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.01.003 · Cited by 359
Sahoo, D. K., Heilmann, R. M., Paital, B., Patel, A., Yadav, V. K., Wong, D., & Jergens, A. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217165 · Cited by 339
Singh, V., Yeoh, B. S., Chassaing, B., Zhang, B., Saha, P., Xiao, X., Awasthi, D., Shashidharamurthy, R., Dikshit, M., Gewirtz, A., et al. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.03.007 · Cited by 117
Zollner, A., Schmiderer, A., Reider, S. J., Oberhuber, G., Pfister, A., Texler, B., Watschinger, C., Koch, R., Effenberger, M., Raine, T., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa124 · Cited by 95
Toyonaga, T., Matsuura, M., Mori, K., Honzawa, Y., Minami, N., Yamada, S., Kobayashi, T., Hibi, T., & Nakase, H. (2016) · Scientific Reports · doi:10.1038/srep35014 · Cited by 75
Metadata
- Authors
- Stallhofer, J., Friedrich, M., Konrad-Zerna, A., Wetzke, M., Lohse, P., Glas, J., Tillack-Schreiber, C., Schnitzler, F., Beigel, F., & Brand, S.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08
- Volume
- 21
- Issue
- 10
- Pages
- 1
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2461323280
- Cited by
- 130
- References
- 10
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status. https://app.cochat.ai/papers/10.1097/mib.0000000000000515
- The paper
- Stallhofer, J., Friedrich, M., Konrad-Zerna, A., Wetzke, M., Lohse, P., Glas, J., Tillack-Schreiber, C., Schnitzler, F., Beigel, F., & Brand, S. (2015). Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000000515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.